BioCentury
ARTICLE | Company News

FDA to review Galenica's PA21 for CKD

April 16, 2013 12:41 AM UTC

Galenica Ltd. (SIX:GALN) and its specialty pharma business Vifor Pharma Ltd. said FDA accepted for review an NDA for PA21 to treat hyperphosphatemia in patients with chronic kidney disease (CKD). The ...